慢性乙型肝炎患者血清干扰素α水平的检测和临床意义
被引量:1
摘要
IFN是人体内的一种细胞因子,在健康人体内维持一定水平,具有抗病毒、免疫调节等多种功能。慢性乙型肝炎(慢乙肝)患者体内的IFN在疾病的发生发展过程中发挥重要作用,国内外普遍应用外源性IFN治疗慢乙肝。
出处
《中华传染病杂志》
CAS
CSCD
北大核心
2011年第5期309-311,共3页
Chinese Journal of Infectious Diseases
参考文献13
-
1Mizukoshi E, Sidney J, Livingston B, et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol, 2004,173 : 5863-5871.
-
2Paul S, Tabassum S, Islam MN. A study on interferon gamma (IFN gamma) response by T ceils stimulated by hepatitis B virus core antigen. Bangladesh Med Res Counc Bull, 2004,30 : 9-15.
-
3Pontesilli O, van Nunen AB, van Riel D, et al. Hepatitis B virus specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon alpha. Liver Int, 2004,24 : 308-315.
-
4Hosaka T, Suzuki F, Suzuki Y, et al. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine resistant mutants of hepatitis B virus. Intervirology, 2004, 47,362- 369.
-
5Kacprzak-Bergman I, Bergman P, Zaleska I. Influence of chronic HBV infection and interferon therapy on somatic development of children. Med Wieku Rozwoj, 2004, 8:65- 73.
-
6Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol, 2004, 74: 406- 413.
-
7Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am, 2004,33:629 -654,.
-
8Kasztelan Szczerbinska B, Stomka M, Celiflski K, et al. Interferon-alfa treatment may reduce the occurrence of liver carcinogenesis in patients with chronic viral hepatitis. Ann Univ Mariae Curie Sklodowska Meal, 2003,58.280- 285.
-
9中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14007
-
10Tjemsland L, Sareide JA, Matre R, et al. Pre operative [correction of Properative] psychological variables predict immunological status in patients with operable breast cancer. Psychooncology, 1997, 6.311-320.
二级参考文献15
-
1Mizukoshi E,Sidney J,Livingston B,et al.Cellular immune responses to the hepatitis B virus polymerase[J].J Immunol,2004,173:5863-5871.
-
2Paul S,Tabassum S,Islam MN.A study on interferon-gamma(IFN-gamma)response by Tcells stimulated by hepatitis B virus core antigen[J].Bangladesh Med Res Counc Bull,2004,30:9-15.
-
3Pontesilli O,Van Nunen AB,Van Riel D,et al.Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha[J].Liver Int,2004,24:308-15.
-
4Hosaka T,Suzuki F,Suzuki Y,et al.Adefovir dipivoxil for treatment of breakthrough hepatitis caused by Lamivudine-resistant mutants of hepatitis B virus[J].Intervirology,2004,47:362-369.
-
5Kacprzak-Bergman I,Bergman P.Influence of the chronic HBV infection and interferon therapy on somatic development of children[J].Med Wieku Rozwoj,2004,8:65-73.
-
6Tsuda N,Yuki N,Mochizuki K,et al.Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy[J].J Med Virol,2004,74:406-413.
-
7Lai CJ,Terrault NA.Antiviral therapy in patients with chronic hepatitis B and cirrhosis[J].Gastroenterol Clin North Am,2004,33:629-654.
-
8Kasztelan-Szczerbinska B,Slomka M,Celinski K,et al.Interferon-alfa treatment may reduce the occurrence of liver carcinogenesis in patients with chronic viral hepatitis[J].Ann Univ Mariae Curie Sklodowska,2003,58:280-285.
-
9Novick D,Cohen B,Rubinstein M.The human interferon alpha beta receptor:characterization and molecular cloning[J].Cell,1994,77:391-400.
-
10Cavanaugh VJ,Guidotti LG,Chisari FV.Interleukin-12 inhibits hepatitis B Virus replication in transgenic mice[J].J Virol,1997,71:3236-3243.
共引文献14009
-
1刘洋.复方木鸡颗粒联合替诺福韦治疗代偿期乙型肝炎肝硬化患者的临床研究[J].慢性病学杂志,2019,0(12):1853-1854.
-
2曾远松,黄柳春.茵郁芪灵汤联合恩替卡韦治疗慢性乙型肝炎的疗效观察[J].内蒙古中医药,2021,40(5):13-14. 被引量:2
-
3宫笑一,刘守华.代偿期乙肝肝硬化患者服用恩替卡韦对血清甲状腺激素水平的影响[J].中国农村卫生,2018,0(16):78-78.
-
4王雪艳,张旭东.甘草酸二铵对乙肝肝硬化患者TBIL、CⅣ及炎性因子的影响分析[J].医药论坛杂志,2021,42(16):7-10.
-
5欧阳福生.老年病毒性肝炎267例临床报告[J].山东大学学报(医学版),2014,52(S01):83-84.
-
6潘晓华.阿德福韦酯联合拉米夫定治疗乙肝肝硬化患者80例8年的临床报道[J].世界最新医学信息文摘,2020(48):108-109.
-
7付振双.恩替卡韦治疗失代偿期慢性乙型病毒性肝炎肝硬化的临床研究[J].世界最新医学信息文摘,2020(2):150-150. 被引量:1
-
8陈新梅,陈昆迪.重型肝病转归与季节关系的探讨[J].医学信息,2018,31(A02):62-63.
-
9王同兴,于卫叶.联合检测血清PCⅢ,HA,LN对肝纤维化的诊断价值[J].医学信息(医学与计算机应用),2016,29(28):217-218. 被引量:2
-
10潘晓华.还原性谷胱甘肽治疗慢性乙型肝炎患者162例疗效观察[J].医学信息(医学与计算机应用),2014,0(31):250-250.
同被引文献9
-
1柳雅立,陈新月.干扰素治疗慢性乙型肝炎的影响因素及疗效预测[J].中华肝脏病杂志,2010,18(6):410-413. 被引量:15
-
2禹福科,郭亚.慢性乙型肝炎患者血清中干扰素-γ、白细胞介素-4和白细胞介素-10水平检测与病毒载量的关系[J].临床医学,2011,31(4):18-20. 被引量:7
-
3孔霞,于慧琴,张萌.慢性乙型肝炎患者外周血淋巴细胞干扰素治疗后的变化[J].中国实用医刊,2011,38(13):123-124. 被引量:2
-
4徐严,斯庆图娜拉,张曼华,焦健,张永贵,季尚玮,赵平,郭宏华,李岩,周长玉,王江滨.聚乙二醇干扰素α-2a个体化治疗慢性乙型肝炎患者的临床疗效[J].中华肝脏病杂志,2011,19(9):670-673. 被引量:11
-
5洪美珠,方匡南,毛乾国,黄文琪,夏挺,宋闽宁,张如棉,潘金水.干扰素α治疗慢性乙型肝炎疗效预测的评分量表[J].中华肝脏病杂志,2011,19(10):738-742. 被引量:1
-
6王蜀强,徐开菊,吴家箴,刘晓姝,罗婷婷,杨仁国,耿晓霞,黄仁刚,林健梅,杨兴祥,江南.不同疗程干扰素联合核苷(酸)类似物治疗HBeAg阳性慢性乙型肝炎的疗效[J].中华肝脏病杂志,2011,19(10):785-786. 被引量:17
-
7万谟彬.干扰素优化治疗慢性乙型肝炎的依据和实施建议——《干扰素治疗慢性乙型肝炎专家建议(2010年更新)》解读[J].中华传染病杂志,2011,39(10):579-582. 被引量:13
-
8郑莹,魏来,毛乾国.细胞毒性T淋巴细胞对慢性乙型肝炎干扰素α抗病毒疗效的预测[J].中华医院感染学杂志,2011,21(24):5125-5127. 被引量:2
-
9马保凤,王千钧,史昌河.血小板减少对干扰素治疗慢性乙型肝炎患者疗效的影响[J].中华实验和临床感染病杂志(电子版),2013,7(2):44-47. 被引量:2
-
1郭卫刚,柴广丽,叶迎宾,郭倩丽.慢性乙型肝炎患者血清干扰素α检测和临床意义[J].成都医学院学报,2012,7(03Z):443-444.
-
2苏江,朱静,周彬.系统性红斑狼疮患者血清干扰素α2表达水平及其相关性分析[J].西部医学,2015,27(11):1689-1691.
-
3杨洲.“幽门螺杆菌”那些事儿[J].家庭用药,2016,0(9):75-75.
-
4刘德敏.细说糖化血红蛋白[J].糖尿病之友,2015,0(7):44-44.
-
5周小勇,李新宇,郑家润.咪喹莫特对BALB/c小鼠细胞因子生成的影响[J].中华皮肤科杂志,2005,38(5):271-272. 被引量:1
-
6幼年皮肌炎患者血清干扰素α活性升高[J].中华医学信息导报,2009,24(12):9-9.
-
7朱延华(摘译),严晋华(审校),翁建平(审校).胰岛素可增加正常人体内血糖刺激后胰岛素分泌[J].中华糖尿病杂志,2011,3(1):91-91.
-
8刘德敏.糖化血红蛋白与即时血糖检测不同的临床意义[J].糖尿病之友,2007(9):95-95.
-
9金敏.高海拔地区心血管疾病与微量元素硒及相关生物活性物质的临床研究[J].微量元素与健康研究,2004,21(2):6-8. 被引量:2
-
10高帅芸.内皮祖细胞与动脉粥样硬化相关性研究进展[J].长治医学院学报,2015,29(5):390-393. 被引量:1